The Ministry of industry and trade of the Russian Federation will develop tools to support exporting drugs

The Ministry of industry and trade of the Russian Federation will develop tools to support exporting drugs


The Deputy head of the Ministry of industry and trade Sergey Tsyb noted that the trend of foreign manufacturers working in Russia, and then export products from the Russian sites, will also increase.

The INDUSTRIAL PARK VORSINO (Kaluga region), 20 Oct. The Ministry of industry and trade will be to modify the instruments of export support for Russian pharmaceutical manufacturers, while the foreign companies that localized their production in Russia, there are great prospects for development, told journalists the Deputy head of the Ministry Sergey Tsyb.

“All instruments relating to the support of exports, we will put in the forefront now, supporting those companies that export their products,” said Tsyb.

British-Swedish pharmaceutical company AstraZeneca on Tuesday announced the opening in Kaluga oblast a new plant a cost of 224 million dollars. To operate the plant will start early next year. We are talking mainly about the final stage of production of the products, their packaging and quality control. At full capacity the plant will start operating in 2017 and will produce some 40 million packages and 850 million tablets about 30 medications each year. This amount will be more than 60% of AstraZeneca medicines sold in the Russian Federation.

“And I think great opportunities exist for foreign players, creating a production here, and then export products from the Russian sites in all countries where they are traditionally produced drugs. It seems to me that this trend will grow,” he added.

According to Tsyb, current economic conditions played into the hands of pharmaceutical producers in Russia, increasing their competitiveness by reducing the cost of their products.

“The ruble devaluation has played a big role for the competitiveness of Russian companies, producing products in Russia, from the point of view of production cost”, — he noted.